Tetanus Toxoid Vaccine Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 12.05 Billion |
| Market Size (2029) | USD 17.19 Billion |
| CAGR (2024 - 2029) | 5.05 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Tetanus Toxoid Vaccine Market Analysis
The Tetanus Toxoid Vaccine Market size is estimated at USD 12.05 billion in 2024, and is expected to reach USD 17.19 billion by 2029, growing at a CAGR of 5.05% during the forecast period (2024-2029).
Factors such as increasing cases of tetanus and diphtheria, rising research activities for developing novel vaccines, and government initiatives for vaccination are anticipated to contribute to the market growth during the forecast period.
Tetanus, commonly called lockjaw, is a severe, non-contagious illness. It is caused by a bacterial toxin that disrupts the nervous system, resulting in painful muscle spasms, especially in the jaw and neck. The huge burden of tetanus and diphtheria cases is likely to fuel the demand for vaccines to propel the market growth. For instance, according to the data published by the World Health Organization in October 2023, 538 cases of diphtheria were reported in Guinea in 2023. Similarly, according to the data published by the World Health Organization in August 2023, 5,898 cases of diphtheria were reported in Nigeria in 2023. Thus, the significant prevalence of diphtheria is anticipated to drive the need for tetanus toxoid vaccines, contributing to market growth.
Also, government initiatives to ensure vaccination among the population are likely to drive market growth. For instance, in August 2023, according to the World Health Organization recommendation, an individual undergoes a vaccination regimen consisting of six tetanus-toxoid-containing vaccines (TTCV) doses, comprising three primary doses and three subsequent booster doses. Additionally, in August 2022, the Public Health and Family Welfare Minister of Madhya Pradesh, India, launched the state-level DPT/TD vaccination campaign program at the Kamala Nehru Girls School Auditorium, Bhopal. Thus, such initiatives are anticipated to drive the demand for tetanus toxoid vaccine and boost the market growth.
Moreover, product launches and collaborations to develop tetanus vaccination and immunization are other driving factors of the tetanus toxoid vaccine market. For instance, in August 2022, IBSS Biomed SA funded a clinical investigation to evaluate the immunogenic and safety profile of a booster immunization with tetanus and diphtheria bivalent vaccine CLODIVAC (developed by IBSS Biomed SA) and Td-Impfstoff Mérieux (produced by Sanofi Pasteur) in healthy adult populations. Thus, market player efforts to boost research and development for novel vaccines are expected to drive market growth.
Therefore, the above-mentioned factors, such as the high burden of tetanus and diphtheria cases, rising government initiatives and programs, and market player efforts, are expected to drive the market growth of the tetanus toxoid vaccine. However, the side effects associated with the toxoid vaccine restrain the market growth during the forecast period.
Tetanus Toxoid Vaccine Market Trends
The Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment is Expected to Hold a Significant Market Share in the Tetanus Toxoid Vaccine Market During the Forecast Period
The diphtheria, tetanus, and pertussis (DTaP) vaccine segment is anticipated to witness growth in the tetanus toxoid vaccine market owing to factors such as growing government initiatives to eradicate these diseases, a rise in product launches, and an increase in pipeline studies for the development of DTaP vaccines. The DTaP vaccine protects young children against diphtheria, tetanus, and whooping cough (pertussis), three potentially fatal illnesses.
Due to the significant burden of diphtheria, tetanus, and pertussis cases is likely to fuel the demands for diphtheria, tetanus, and pertussis (DTaP) vaccines and boost the segment growth. For instance, according to a vaccine-preventable disease update by the World Health Organization (WHO) in October 2022, seven countries (Austria, France, Germany, Italy, Norway, Switzerland, and the United Kingdom) reported 144 cases of diphtheria, many of which were among asylum seekers. Of the 144 cases, 97 (69%) were classified as clinically compatible, 44 (31%) were laboratory-confirmed as toxigenic diphtheria cases, and 3 (2%) were suspected cases. Moreover, as per an August 2023 update from the World Health Organization (WHO), in 2022, a significant 84% of infants around the globe were protected against severe diseases like diphtheria, tetanus, and pertussis by receiving three doses of the DTP vaccine. Also, per the 2023 Provisional Pertussis Surveillance Report published by the Centers for Disease Control and Prevention (CDC), 5,611 cases of pertussis were reported in the United States in 2023, up from 2,388 cases in 2022. Hence, an increase in pertussis cases is likely to demand vaccine availability, thereby driving the segment growth.
Additionally, government initiatives to increase the accessibility of the diphtheria-tetanus-pertussis (DTP) vaccine are anticipated to boost the segment's growth. For instance, in December 2023, eligible Gavi-supported countries can now submit applications to incorporate diphtheria, tetanus, and pertussis (DTP)-containing booster doses (DTP boosters) into their immunization schedules. Thus, such initiatives are anticipated to boost the adoption of diphtheria, tetanus, and pertussis (DTP) vaccines and fuel the segment growth.
Therefore, due to factors such as the growing burden of diphtheria, tetanus, and pertussis, government initiatives are likely to impact the market growth positively.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
North America is expected to hold a significant market share in the tetanus toxoid vaccine market due to the increase in government vaccination programs, the surge in diphtheria, pertussis, and tetanus cases, and the rise in research initiatives for vaccine development.
The high prevalence of pertussis cases in the region drives the demand for tetanus toxoid vaccines and boosts market growth. For instance, according to a January 2024 update from the Department of Minnesota, 61 cases of pertussis were reported in the Minnesota region till December 2023. Also, as per the Florida Health Report, in 2023, 10 pertussis cases were reported in 6 counties. A 10% increase in pertussis cases was reported between August 2022 and January 2023 compared to August 2021 and January 2022. Thus, the increase in the prevalence of pertussis cases in the region is expected to fuel the need for tetanus toxoid vaccines and contribute to the market growth.
Also, the rise in government initiatives for vaccinations against tetanus and diphtheria is expected to boost the market growth during the forecast period. For instance, in April 2022, Ontario expanded its publicly funded Tdap immunization program to include a routine dose in every pregnancy for protection against pertussis, regardless of previous Tdap immunization history. Canada's National Advisory Committee on Immunization recommended that all pregnant individuals get the pertussis (whooping cough) vaccine during each pregnancy to safeguard newborns after birth.
Tetanus Toxoid Vaccine Industry Overview
The tetanus toxoid vaccine market is fragmented and competitive. It consists of several major players. Some of the prominent players currently dominating the market are Merck KGaA, GSK PLC, Sanofi (Sanofi Pasteur Inc.), Pfizer Inc., Bharat Biotech, Astellas Pharma Inc., Panacea Biotec Ltd, BB-NCIPD Ltd, PT Bio Farma, and Biological E Limited.
Tetanus Toxoid Vaccine Market Leaders
-
Sanofi (Sanofi Pasteur, Inc)
-
Pfizer, Inc
-
Bharat Biotech
-
Merck KGaA
-
GSK plc
*Disclaimer: Major Players sorted in no particular order
Tetanus Toxoid Vaccine Market News
- May 2024: ILiAD Biotechnologies reported positive results from the Phase 2b School-age Trial of BPZE1 Pertussis Vaccine, conducted among children aged 6 to 17 in the United Kingdom, Australia, and Costa Rica. This clinical trial aims to assess the immune response and safety of a single intranasal dose of BPZE1, both with and without the simultaneous administration of tetanus, diphtheria, and acellular pertussis vaccine (Tdap, Boostrix).
- December 2023: Panacea Biotec introduced the fully liquid whole cell pertussis vaccine-inactivated poliovirus vaccine (wP-IPV) pentavalent vaccine EasyFourPol in India to protect children against five serious diseases such as five deadly diseases: diphtheria, tetanus, pertussis, polio, and invasive infections caused by Haemophilus influenzae type B.
Tetanus Toxoid Vaccine Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Cases of Tetanus and Diphtheria in Some Countries
- 4.2.2 Growing Research and Development Activities for New Vaccines
- 4.2.3 Increasing Government Initiatives Programs for Vaccination
-
4.3 Market Restraints
- 4.3.1 Side-effects Associated with Toxoid Vaccine
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Vaccine Type
- 5.1.1 Diphtheria, Tetanus, and Pertussis (DTaP)
- 5.1.2 Diphtheria and Tetanus (DT)
- 5.1.3 Tetanus, Diphtheria, And Pertussis (Tdap)
- 5.1.4 Other Vaccine Types
-
5.2 By End User
- 5.2.1 Hospitals and Clinics
- 5.2.2 Other End Users
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Merck KGaA
- 6.1.2 GSK Plc
- 6.1.3 Sanofi (Sanofi Pasteur Inc.)
- 6.1.4 Pfizer Inc.
- 6.1.5 Bharat Biotech
- 6.1.6 Astellas Pharma Inc.
- 6.1.7 Panacea Biotec Ltd
- 6.1.8 BB - NCIPD Ltd
- 6.1.9 PT Bio Farma
- 6.1.10 Biological E Limited
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Tetanus Toxoid Vaccine Industry Overview
As per the scope of the report, the tetanus vaccine, also known as tetanus toxoid, is a toxoid vaccine used to prevent tetanus. Five doses are recommended during childhood, with a sixth given during adolescence. After three doses, almost everyone is initially immune, but additional doses every 10 years are recommended to maintain immunity.
The tetanus toxoid vaccine market is segmented by vaccine type, end user, and geography. By vaccine type, the market is segmented into diphtheria, tetanus, and pertussis (DTaP), diphtheria and tetanus (DT), tetanus, diphtheria, and pertussis (Tdap), and other vaccines. By end user, the market is segmented into hospitals and clinics and other end users. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. For each segment, the market size is provided in terms of USD value.
| By Vaccine Type | Diphtheria, Tetanus, and Pertussis (DTaP) | |
| Diphtheria and Tetanus (DT) | ||
| Tetanus, Diphtheria, And Pertussis (Tdap) | ||
| Other Vaccine Types | ||
| By End User | Hospitals and Clinics | |
| Other End Users | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Tetanus Toxoid Vaccine Market Research FAQs
How big is the Tetanus Toxoid Vaccine Market?
The Tetanus Toxoid Vaccine Market size is expected to reach USD 12.05 billion in 2024 and grow at a CAGR of 5.05% to reach USD 17.19 billion by 2029.
What is the current Tetanus Toxoid Vaccine Market size?
In 2024, the Tetanus Toxoid Vaccine Market size is expected to reach USD 12.05 billion.
Who are the key players in Tetanus Toxoid Vaccine Market?
Sanofi (Sanofi Pasteur, Inc), Pfizer, Inc, Bharat Biotech, Merck KGaA and GSK plc are the major companies operating in the Tetanus Toxoid Vaccine Market.
Which is the fastest growing region in Tetanus Toxoid Vaccine Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Tetanus Toxoid Vaccine Market?
In 2024, the North America accounts for the largest market share in Tetanus Toxoid Vaccine Market.
What years does this Tetanus Toxoid Vaccine Market cover, and what was the market size in 2023?
In 2023, the Tetanus Toxoid Vaccine Market size was estimated at USD 11.44 billion. The report covers the Tetanus Toxoid Vaccine Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Tetanus Toxoid Vaccine Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Tetanus Toxoid Vaccine Industry Report
Statistics for the 2024 Tetanus Toxoid Vaccine market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Tetanus Toxoid Vaccine analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
